The abnormally high expression of RPN2 in a variety of cancer subtypes plays an important role in the drug resistance and invasion progression of cancer cells by regulating the N-terminal glycosylation of various proteins such as p-glycoprotein, CD63, and epidermal growth factor receptor (EGFR) (23–27). Here, CD63 is linked to cancer.